Although direct evidence in PC is still limited, the genetic and molecular similarities between prostate, breast, and ovarian cancers support further exploration of redox and epigenetic therapies in PC, particularly in molecularly defined subgroups with GSTM5 dysregulation [39,40]. Here, GSTM5 is linked to pachyonychia congenita.